44 patents
Utility
Humanized anti-CD73 antibodies
2 Jan 24
Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73.
Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
Filed: 24 Sep 20
Utility
Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
5 Dec 23
An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments.
Jay M. Short, Gerhard Frey, Hwai Wen Chang, William Boyle
Filed: 4 Jun 19
Utility
Method for Preparing a Conditionally Active Antibody or Antibody Fragment
23 Nov 23
A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition.
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Filed: 27 Jun 23
Utility
Mirac Proteins
19 Oct 23
This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions.
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Filed: 14 Jun 23
Utility
Conditionally active polypeptides and methods of generating them
3 Oct 23
A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition.
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Filed: 13 Aug 21
Utility
Mirac proteins
8 Aug 23
This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions.
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Filed: 8 Sep 17
Utility
Conditionally Active ANTI-CD46 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof
3 Aug 23
Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to CD46 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CD46 protein.
Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG, Jing WANG, Chao XING
Filed: 15 Jun 21
Utility
Conditionally Active ANTI-NECTIN-4 Antibodies
27 Jul 23
Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to Nectin-4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Nectin-4 protein.
Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG, Jing WANG, Chao XING, Haizhen LIU, Ana Paula CUGNETTI
Filed: 15 Jun 21
Utility
Methods of protein evolution
2 May 23
The present invention is relevant to proteins and novel methods of protein evolution.
Jay M. Short
Filed: 30 Sep 20
Utility
Conditionally Active Anti-Her2 Antibodies, Antibody Fragments Their Immunoconjugates And Uses Thereof
6 Apr 23
A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to HER2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to HER2 protein and multi-specific antibodies that bind to HER2 protein and CD3.
Jay M. SHORT, Gerhard FREY, Hwai Wen Chang
Filed: 22 Jan 21
Utility
Chimeric Antigen Receptors to HER2 and Methods of Use Thereof
9 Mar 23
The present disclosure provides chimeric antigen receptors (CARs), and nucleic acids comprising nucleotide sequences encoding the CARs, that bind to HER2, and conditionally active biologic (CAB) CARs that bind to HER2.
Gregory Ian Frost, James Joseph Onuffer, JR., Anirban Kundu, Jay M. Short, Gerhard Frey, Hwai Wen Chang
Filed: 23 Jan 21
Utility
Conditionally active chimeric antigen receptors for modified T-cells
21 Feb 23
This disclosure relates to a chimeric antigen receptor for binding with a target antigen.
Jay M. Short
Filed: 2 Aug 18
Utility
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
3 Jan 23
A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein.
Jay M. Short, Gerhard Frey, Hwai Wen Chang
Filed: 25 Oct 19
Utility
Conditionally Active Polypeptides
22 Dec 22
A non-naturally occurring polypeptide or isolated polypeptide having a ratio of at least 1.3 of an activity in an assay at a first pH in the presence of at least one species having a molecular weight of less than 900 a.m.u. and a pKa up to 4 pH units away from said first pH, to an activity in an assay at a second pH in the presence of the same at least one species.
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Filed: 19 Aug 22
Utility
Comprehensive Monoclonal Antibody Generation
8 Dec 22
The present invention relates to methods for efficiently generating recombinant monoclonal antibodies derived from B cells of a non-human host which has been immunochallenged with one or more target antigens.
Jay M. Short
Filed: 22 Jun 22
Utility
Proteins Targeting Orthologs
27 Oct 22
The present invention is relevant to polypeptides and novel methods of polypeptide evolution.
Jay M. Short
Filed: 24 Feb 22
Utility
Conditionally active polypeptides
18 Oct 22
A non-naturally occurring polypeptide or isolated polypeptide having a ratio of at least 1.3 of an activity in an assay at a first pH in the presence of at least one species having a molecular weight of less than 900 a.m.u. and a pKa up to 4 pH units away from said first pH, to an activity in an assay at a second pH in the presence of the same at least one species.
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Filed: 31 Aug 16
Utility
Express Humanization of Antibodies
13 Oct 22
The disclosure provides a method for generation of humanized full length antibodies in mammalian cells.
Jay M. Short
Filed: 21 Jun 22
Utility
Conditionally Active Anti-epcam Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof
6 Oct 22
Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
Jay M. Short, Gerhard Frey, Hwai Wen Chang
Filed: 10 Jun 20
Utility
Protein Therapeutics for Treatment of Senescent Cells
8 Sep 22
Methods of generating conditionally active proteins that target senescent cells and which are conditionally active in an extracellular environment of a senescent cell.
Jay Short
Filed: 16 May 22